https://www.thebodypro.com/category/hiv-treatments-in-development/tag/croi-conference-on-retroviruses-and-opportunistic-infections
HIV Treatments in Development

CROI (Conference on Retroviruses and Opportunistic Infections)

The Latest

clinical trial

Clinical Trial Data Needs to Reflect the Demographics of HIV, Say Activists

A recent analysis conducted by the AIDS Treatment Activists Coalition revealed that, among HIV drug trial participants, data specific to race and sex were dramatically underreported.

By Terri Wilder, M.S.W.
injectable

Long-Acting ART Is Here. How Do We Make It Work for Our Patients?

Injectable HIV interventions are a game-changing new option for people dealing with pill fatigue, but there are implementation challenges for clinicians to consider.

By Larry Buhl
photo of David Alain Wohl, M.D., as he recaps research from CROI 2021

Broadly Neutralizing Antibodies for HIV? If We Can Do It for COVID ...

David Alain Wohl, M.D., shares his thoughts on broadly neutralizing antibodies for COVID-19—and the extent to which we can hope to see similar developments in HIV.

By David Alain Wohl, M.D.
photo of David Alain Wohl, M.D., as he recaps research from CROI 2021

CROI 2021 Takeaway: Long-Acting Antiretrovirals for HIV Treatment

David Alain Wohl, M.D., talks through new data regarding long-acting antiretroviral therapy for HIV—and touches on the uncertainties clinicians face in incorporating this new treatment method into their practice.

By David Alain Wohl, M.D.
injection vials

Long-Acting HIV Treatment and PrEP Pipeline Update: So Many Formulations!

CROI 2021 featured new research on a host of long-acting antiretrovirals in development, including less-frequent treatment injections, a weekly pill for HIV treatment, injectable PrEP, vaginal PrEP rings, and PrEP implants.

By Larry Buhl
injectable

The Monthly Injectable HIV Drug Works Just as Well When Given Every Two Months

Although injectable cabotegravir/rilpivirine is still yet to be approved by the FDA, evidence keeps mounting on the effectiveness of the shot for HIV treatment.

By Sony Salzman
stem cell transplant device

Durable HIV Remission in London Patient, the Second Person Cured of HIV

Researchers are happy but cautious, because this isn’t a strategy for most people with HIV.

By Sony Salzman
Marrazzo at CROI

CROI 2020: What to Expect in HIV Science From This Year’s Conference

COVID-19 will impact both the program content and attendees this year, but there are still important HIV science presentations.

By Sony Salzman
The Genetic Mutation Behind the Only Apparent Cure for HIV Img

The Genetic Mutation Behind the Only Apparent Cure for HIV

The HIV-resistant gene mutation CCR5 delta 32 has an interesting past. Could it also be the future of HIV treatment and prevention?

By Martha Kempner
Phase 3 Results With Dual Therapy Cabotegravir/Rilpivirine Long-Acting Injections: ATLAS and FLAIR Studies Img

Phase 3 Results With Dual Therapy Cabotegravir/Rilpivirine Long-Acting Injections: ATLAS and FLAIR Studies

Two oral presentations at CROI 2019 showed that dual therapy with long-acting monthly injections resulted in very low levels of virological failure with high participant preference for injections compared to oral combinations.

By Simon Collins for HIV i-Base